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Abstract: Different animal models have been proposed to investigate the mechanisms of Human
T-lymphotropic Virus (HTLV)-induced pathogenesis: rats, transgenic and NOD-SCID/γcnull
(NOG) mice, rabbits, squirrel monkeys, baboons and macaques. These systems indeed provide
useful information but have intrinsic limitations such as lack of disease relevance, species specificity
or inadequate immune response. Another strategy based on a comparative virology approach
is to characterize a related pathogen and to speculate on possible shared mechanisms. In
this perspective, bovine leukemia virus (BLV), another member of the deltaretrovirus genus, is
evolutionary related to HTLV-1. BLV induces lymphoproliferative disorders in ruminants providing
useful information on the mechanisms of viral persistence, genetic determinants of pathogenesis and
potential novel therapies.
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1. Introduction
BLV naturally infects cattle, zebu and water buffalo but can also be experimentally transmitted
to sheep, goats or alpaca (Vicugna pacos) [1–3]. In cattle, the most prevalent clinical manifestation is a
benign accumulation of infected B-lymphocytes called persistent lymphocytosis (PL) affecting about
one-third of infected animals [4,5]. In a minority of cases (about 5%–10%), BLV infection can progress
to fatal leukemia/lympoma whose most spectacular consequence is spleen disruption consecutive
to tumor formation [6]. BLV typically persists in less than 1% of peripheral blood cells, leading to
an asymptomatic infection in the majority of infected animals. BLV is transmitted horizontally by
direct contact, iatrogenic procedures or insect bites upon transfer of infected cells from milk, blood
and body fluids from heavily infected dams [7,8].
Among experimental hosts, sheep provide a useful model to address specific questions
pertaining to immunity, viral persistence and pathogenesis. In particular, reverse genetics permitted
the development of a life-attenuated vaccine and a novel therapeutic approach. Main advantages
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of the sheep model include a high frequency of leukemia/lymphoma (close to 100%) and a shorter
latency period (typically 2–4 years).
BLV-associated pathogenesis thus shares a series of features with HTLV-1-induced Adult
T-cell Leukemia (ATLL) but does apparently not include neurodegenerative diseases such as
HTLV-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) [9]. It is assumed that
consumption of raw milk from BLV-infected cattle is not associated with an increased risk of cancer
in human, although the link cannot be formally excluded [10].
The goal of this review is to outline interesting observations in the BLV model that are of interest
to understand HTLV-1 replication and pathogenesis.
2. Viral Oncogenes Drive Proliferation
As deltaretrovirus, BLV carries the classical genes (gag, pro pol and env) that are required
to complete the viral cycle: genesis and budding of a virion, infection of a target cell, reverse
transcription and integration into the host cell chromosome. The BLV provirus also encodes a
series of additional accessory genes as well as microRNAs that modulate viral and/or cellular gene
expression (Figure 1) [11,12]. Among these, Tax and G4 are oncogenes able to promote transformation
of primary rat embryo fibroblasts [13,14]. Tax activates transcription by acting on a triplicate 21 bp
enhancer motif in the 51 the LTR promoter via the CREB/ATF signaling pathway [15,16]. Although,
the mechanisms of cell transformation remain to be further characterized, it is interesting to note
that BLV and HTLV-1 Tax share cellular targets. Both transactivators indeed bind to tristetraprolin
(TTP), a post-transcriptional modulator of TNFα expression [17]. The Tax proteins promote nuclear
accumulation of TTP and restore TNFα expression by inhibiting TTP.
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Figure 1. Schematic structure of (a) the bovine leukemia virus (BLV) genome and (b) the viral particle. 
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farnesyl pyrophosphate synthase (FPPS), an enzyme involved in the mevalonate/squalene pathway 
and in synthesis of FPP, a substrate required for prenylation of Ras [18]. In addition FPPS is 
involved in synthesis of isoprenoids modulating the membrane fluidity and stability of lipid rafts [19]. 
Being localized in the nuclear compartment and in mitochondria, G4 and p13 thus exert 
evolutionary conserved functions. 
Recently, a proviral region located 3′ of the env gene was shown to express microRNAs under 
the control of RNA polymerase III promoters (miR on Figure 1) [20]. The BLV microRNAs associate 
with Argonaute and mimic cellular analogs (e.g., BLV-miR-B4 for miR-29). BLV microRNAs are 
transcribed from a region dispensable for in vivo infectivity but are abundantly expressed in 
i r . c tic str ct r f ( ) t i l i ir s ( V) genome and (b) the viral particle.
Another cellular protein concomitantly targeted by BLV G4 and its ortholog in HTLV-1 (p13) is
farnesyl pyrophosphate synthase (FPPS), an enzyme involved in the mevalonate/squalene pathway
and in synthesis of FPP, a substrate required for prenylation of Ras [18]. In addition FPPS is involved
in synthesis of isoprenoids modulating the membrane fluidity and stability of lipid rafts [19]. Being
localized in the nuclear compartment and in mitochondria, G4 and p13 thus exert evolutionary
conserved functions.
Recently, a proviral region located 31 of the env gene was shown to express microRNAs under the
control of RNA polymerase III promoters (miR on Figure 1) [20]. The BLV microRNAs associate with
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Argonaute and mimic cellular analogs (e.g., BLV-miR-B4 for miR-29). BLV microRNAs are transcribed
from a region dispensable for in vivo infectivity but are abundantly expressed in leukemic B cells
(about 40%) [21]. This evidence thus contradicts the dogma that naturally occurring RNA viruses
will not encode miRNAs to avoid unproductive cleavage of their genomes. HTLV-1 does not encode
microRNAs as indicated by deep sequencing. The role of the BLV microRNAs in viral replication,
persistence and disease remains to be further characterized.
BLV thus encodes transformation drivers (Tax, G4) and viral microRNAs likely important
in pathogenesis.
3. Reverse Genetics Reveals the Significance of Viral Sequences in Infection and Replication
Reverse genetics using a cloned BLV provirus has allowed the screening of regions required
for infection, replication and pathogenesis. As expected, large deletions within the gag, pol or env
genes destroy infectivity in vivo. Discrete regions of the viral genome, such as the ITAM motifs of the
envelope transmembrane protein (TM), are particularly important for infection [22]. Contradicting
the concept that retroviral genomes are highly condensed, sequences located between the env gene
and the Tax/Rex boundary are dispensable for infection [23]. In particular, deletion of R3 and
G4 preserves infectivity but affects replication efficiency [24]. Similarly, deletion of HTLV p12I or
p13II/p30II, the orthologs of BLV R3 and G4, impairs replication in macaques. In contrast, the
mutations do not affect viral replication in rabbits, emphasizing the importance of relevant animal
models [25]. R3 and G4 are nevertheless dispensable for pathogenesis, although their integrity
contributes to disease frequency and latency [26].
Reverse genetics also generated unexpected observations, such as replication at wild-type levels
of proviruses expressing fusion-deficient envelope proteins (TM A60V and A64S) [27]. These mutants
are thus in principle unable to undergo an infectious cycle and may replicate preferentially through
mitotic division of the host cell.
Mutations within the LTR further revealed that the viral promoter contained sub-optimal
enhancers (AGACGTCA, TGACGGCA, TGACCTCA) that are essential for viral replication. As
expected, site directed mutagenesis of the enhancers into consensus cyclic-AMP responsive elements
(TGACGTCA) increases promoter efficiency but strongly impairs viral replication [28,29]. The
presence of suboptimal enhancers in all BLV and HTLV-1 isolates suggests an evolutionary conserved
mechanism that may reduce basal transcription and facilitate the escape from immune response.
Collectively, these observations thus emphasize the dichotomy between conclusions drawn from
in vitro experimentations and their relevance in the animal model.
4. A Mutation that Increases Pathogenicity: Potential Hyperpathogenic Strain
Until recently, all mutations introduced in the BLV provirus were silent or at most reduced
replication and pathogenesis in vivo. We recently reported that mutation of a N-linked glycosylation
site (N230) affects the stability of the SU envelope protein and increases cell-to-cell transmission
suggesting that this site restricts infectivity and viral replication [30]. A mutant carrying the N230
mutation replicates faster and is more pathogenic compared to the isogenic wild-type BLV strain. This
observation thus suggests a mechanism of co-evolution restricting excessive pathogenicity that would
indirectly impair mutual persistence of the virus and its host. Occurrence of this type of mutation
may thus represent a potential threat associated with emergence of hyperpathogenic BLV strains and
possibly also of new HTLV variants.
5. In Vivo Kinetics Indicates that BLV-Infected Cells Undergo High Turnover during Chronic
Infection of Sheep
The BLV model has been instrumental to understand the dynamics of cell turnover in vivo.
In principle, lymphocyte homeostasis is the result of a critical balance between cell proliferation
and death. Initial experiments using intravenous injection of bromodeoxyuridine (BrdU)
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demonstrated that B-lymphocytes are proliferating significantly faster in BLV-positive asymptomatic
and persistently lymphocytotic sheep than in uninfected controls. In fact, an excess of 0.9% cells
are produced by proliferation each day and, during leukemia, these rates even rise by up to
tenfold [31]. Excess of cell proliferation was also reported in HTLV-induced HAM/TSP using
a similar strategy based on incorporation of deuterated glucose [32]. In contrast, persistent
lymphocytosis in BLV-infected cattle is characterized by a decreased B cell turnover resulting from
a reduction of cell death and an overall impairment of proliferation, as observed in human chronic
lymphocytic leukemia (CLL) [33,34].
Cell dynamics can also be estimated by intravenous injection of carboxyfluorescein diacetate
succinimidyl ester (CFSE) [35]. Since CFSE labels proteins via their NH2 terminal ends, halving of
fluorescence indicates that a cell has undergone cell division. Fitting cell numbers and fluorescence
intensities revealed massive destruction of B-lymphocytes during chronic infection of sheep. In
contrast, lymphocyte trafficking to and from lymphoid organs was unaffected.
Collectively, quantification of the dynamic parameters deduced from BrdU and CFSE kinetics
shows that the excess of proliferation in lymphoid organs is compensated by increased death in
peripheral blood [36]. Ablative surgery demonstrated that the spleen is a major lymphoid tissue
massively destroying BLV-infected cells [37].
BLV chronic infection is thus characterized by a very dynamic equilibrium between a virus
attempting to proliferate under a tight control exerted by the immune response.
6. Massive Depletion of Clones Located in Genomic Transcriptionally Active Sites
during Infection
As retroviruses, BLV and HTLV-1 replicate via an infectious cycle upon expression of progeny
virions as well as by mitotic division of provirus-carrying cells (clonal expansion). High throughput
sequencing of proviral integration sites revealed the relative importance of these two cycles in viral
replication varies during infection [38,39]. The majority of infected clones are created early before
the onset of an efficient immune response. Two months from inoculation, the main replication route
is mitotic expansion of pre-existing infected clones. Initially, BLV proviral integration significantly
favors transcribed regions of the genome. Negative selection then eliminates 97% of the clones
detected at seroconversion and disfavors BLV-infected cells carrying a provirus located close to a
promoter or a gene. Nevertheless, among the surviving proviruses, clone abundance positively
correlates with proximity of the provirus to a transcribed region. Two opposite forces thus operate
during primary infection and dictate the fate of long term clonal composition: (1) initial integration
inside genes or promoters and (2) host negative selection disfavoring proviruses located next to
transcribed regions.
7. Tight Control of Virus-Positive Cells by the Immune Response
BLV infection is thus characterized by a massive depletion of provirus-carrying cell clones at
early stages and a very dynamic turnover during chronic infection (Section 5). If the host immune
response tightly controls viral replication, it is predicted that cells expressing viral antigens would be
shorter lived. This question was addressed by comparing the survival rates of two cell pools isolated
from the same donor and labeled with different fluorochromes depending on the absence or the
presence of viral proteins induced ex vivo [40]. As predicted, transient viral expression significantly
reduced the lifespan of BLV-infected lymphocytes. Cyclosporine treatment further supported the
concept that an efficient immune response is required to control virus-expressing cells. This evidence
is consistent with the presence of suboptimal LTR promoters that restrict viral reactivation (see
Section 3) enabling escape from immune mediated destruction.
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8. A Therapy Based on Activation of Viral Expression
BLV persistence is thus a very dynamic process characterized by a virus that continuously
attempts to replicate and an active control exerts by the host immune response. As outlined in
Section 2, viral proteins promote infectious and mitotic cycles but also expose the infected cell to
immune control. Evidence for a very strong immune response is supported by the presence of
virus-specific cytotoxic T cells and by high titers of neutralizing antibodies. Persistence of infected
cells is thus possible providing that viral proteins are not expressed, perhaps under the control of
viral microRNAs. In this context, we evaluated the therapeutic effectiveness of a strategy based on
the induction of viral gene expression using valproic acid (VPA), a lysine deacetylase inhibitor [41,42].
VPA efficiently induced viral expression in primary cultures and reduced the number of leukemic
cells in sheep. This strategy was then translated to another B cell neoplasm [43] and to HTLV-1
infected patients with HAM/TSP [44]. The treatment appeared to be safe but unable to permanently
reduce proviral loads over the long term [45]. Instead, combination of VPA and other lysine
deacetylase inhibitors with a standard regimen of ATL (AZT + IFN) is promising in ongoing clinical
trials [46,47].
9. Towards an Efficient Vaccine
Except in the European Union, the herd prevalence of BLV worldwide ranges between 30%
and 90% [48]. Major economic losses result from leukemia/lymphoma-induced death, reduction
in milk production and custom restrictions. Thus, there is an urgent need for an efficient, safe and
cost-effective vaccine against BLV. Previous vaccine candidates faced problems of efficacy (i.e., only
a fraction of animals were protected), persistence (i.e., rapid decrease of immune protection), cost
(e.g., production of purified proteins) or safety (e.g., genetically modified hybrid viruses). Therefore,
we designed another approach based on a life-attenuated BLV strain harboring multiple deletions
and mutations. The rationale was to delete pathogenic genes (i.e., the oncogenic drivers) while
maintaining a low level of infectivity. After a series of failures, we have identified a deleted BLV
provirus that is infectious in cattle but replicates at very low levels. Inoculation of this vaccine elicits
a vigorous anti-BLV immune response comparable to that of a wild-type infection. The vaccine
does not spread to uninfected sentinels maintained during 7 years in the same herd and could
not be detected in colostrum and milk from experimentally infected cows. Passive antibodies are
transmitted to the newborn calves via the maternal colostrum. This anti-viral passive immunity
persists during several months in the calves. However, the BLV mutant fails to transmit from cows to
calves as assessed by nested PCR. In contrast to HIV, there is no significant sequence variation during
infection [49,50]. Finally, vaccinated animals but not uninfected controls resist challenge by a wild
type BLV virus. Trials are currently ongoing to evaluate the efficacy and safety of the vaccine in large
herds in Argentina.
10. Conclusions
Understanding the mechanisms of BLV infection has provided valuable information on viral
transmission, persistence and pathogenesis. In particular, reverse genetics yielded conclusions that
could not be predicted from experiments performed in vitro as exemplified by a provirus containing
an optimized promoter that was nevertheless attenuated. BLV persistence is characterized by a very
dynamic cell turnover, which is rather unusual for a chronic infection. Host immunity is essential
to control viral replication as indicated by surgical spleen ablation. Disruption of viral latency with
epigenetic modulators has therapeutic value in BLV leukemia and may be useful for treatment of
ATL. Finally, availability of an efficient anti-BLV vaccine is informative to develop preventive and
curative measures in HTLV.
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